Logo
x

Search

Subscribe Now

ALX Oncology

ALX Oncology Reports the First Patient Dosing in P-I/II (UMBRELLA) Trial of Evorpacept Plus Sarclisa for Treating R/R Multiple Myeloma (RRMM)

ALX Oncology Reports the First Patient Dosing in P-I/II (UMBRELLA) Trial of Evorpacept Plus Sarclisa for Treating R/R Multiple Mye...

  • September 5, 2024
ALX Oncology Provides Update on P-II (ASPEN-06) Study of Evorpacept to Treat Gastric Cancer

ALX Oncology Provides Update on P-II (ASPEN-06) Study of Evorpacept to Treat Gastric Cancer

  • August 1, 2024
ALX Oncology and Quantum Leap Report the First Patient Dosing of Evorpacept in the P-I Trial (I-SPY-P1-TRIAL) for Breast Cancer

ALX Oncology and Quantum Leap Report the First Patient Dosing of Evorpacept in the P-I Trial (I-SPY-P1-TRIAL) for Breast Cancer

  • March 14, 2023
PharmaShots Weekly Snapshots (February 13 - 17, 2023)

PharmaShots Weekly Snapshots (February 13 - 17, 2023)

  • February 17, 2023
ALX Oncology Reports the First Patient Dosing of Evorpacept in the P-I Study (ASPEN-07) for the Treatment of Urothelial Cancer

ALX Oncology Reports the First Patient Dosing of Evorpacept in the P-I Study (ASPEN-07) for the Treatment of Urothelial Cancer

  • February 17, 2023
PharmaShots Interview: ALX Oncology's Dr. Sophia Randolph Shares Insight on the Clinical Collaboration with Zymework

PharmaShots Interview: ALX Oncology's Dr. Sophia Randolph Shares Insight on the Clinical Collaboration with Zymework

  • February 22, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.